Apoptosis: Implications of basic research for clinical oncology

Lancet Oncology

Volumn 2, Issue 1, 2001, Pages 33-42

  Tamm, Ingo ^a   Schriever, Folke ^b   Dörken, Bernd ^a  

^a Medizinische Klinik Mit Schwerpunkt Nephrologie   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; BCL 2 BINDING PROTEIN, BIM; BCL-2-BINDING PROTEIN, BIM; CARRIER PROTEIN; CASPASE; HEAT SHOCK PROTEIN; MEMBRANE PROTEIN; ONCOPROTEIN;

APOPTOSIS; GENETICS; HUMAN; NEOPLASM; ONCOLOGY; PHYSIOLOGY; RESEARCH; REVIEW;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CASPASES; HEAT-SHOCK PROTEINS; HUMANS; MEDICAL ONCOLOGY; MEMBRANE PROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RESEARCH;

EID: 0035240260     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00193-5     Document Type: Review

References (69)

1. Reed J.C. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol. 11:1999;68-75.
2. Kerr J.F.R., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 26:1972;239-306.
3. Wyllie A.H., Kerr J.F.R., Currie A.R. Cell death, the significance of apoptosis. Int Rev Cytol. 68:1980;251-306.
4. Earnshaw W.C., Martins L.M., Kaufmann S.H. Mammalian caspases: structure, activation, substrates and functions during apoptosis. Annu Rev Biochem. 68:1999;383-424.
5. Bergmann A., Agapite J., Steller H. Mechanisms and control of programmed cell death in invertebrates. Oncogene. 17:1998;3215-3223.
6. Horvitz H.R. Genetic control of programmed cell death in the nematode Caenorhabditis elegans. Cancer Res. 59:(suppl):1999;1701s-1706s.
7. Zou H., Henzel W.J., Liu X., et al. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 90:1997;405-413.
8. Fadeel B., Orrenius S., Zhivotovsky B. Apoptosis in human disease: a new skin for the old ceremony? Biochem Biophys Res Commun. 266:1999;699-717.
9. Strasser A. Dr Josef Steiner cancer research prize lecture: the role of physiological cell death in neoplastic transformation and in anti-cancer therapy. Int J Cancer. 81:1999;505-511.
10. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat Med. 6:2000;513-519.
11. Sherr C.J. The Pezcoller lecture: cancer cell cycle revisited. Cancer Res. 60:2000;3689-3695.
12. Harbour J.W., Dean D.C. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol. 2:2000;E65-67.
13. Pelengaris S., Rudolph B., Littlewood T. Action of Myc in vivo - proliferation and apoptosis. Curr Opin Genet Dev. 10:2000;100-105.
14. Adams J.M., Cory S. The bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326.
15. Green D., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
16. Haraguchi M., Torii S., Matsuzawa S., et al. Apoptotic protease activating factor 1 (Apaf-1)-independent cell death suppression by bcl-2. J Exp Med. 191:2000;1709-1720.
17. Reed J.C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol. 7:1995;541-546.
18. Koller E., Gaarde W.A., Monia B.P. Elucidating cell signalling mechanisms using antisense technology. Trends Pharmacol Sci. 21:2000;142-148.
19. Robertson L.E., Plunkett W., McConnell K., et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 10:1996;456-459.
20. Reed J., Meister L., Cuddy M., et al. Differential expression of the Bcl-2 proto-oncogene in neuroblastomas and other human neural tumors. Cancer Res. 5l:1991;6529-6538.
21. Fadeel B., Zhivotovsky B., Orrenius S. All along the watchtower: on the regulation of apoptosis regulators. FASEB J. 13:1999;1647-1657.
22. Eskes R., Deshagher S., Antonsson B., Martinou J.C. Bid induces the oligomerization and insertion of bax into the outer mitochondrial membrane. Mol Cell Biol. 20:2000;929-935.
23. Jurgensmeier J.M., Xie Z., Deveraux Q., et al. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA. 5:1998;4997-5002.
24. Thornberry N. The caspase family of cysteine proteases. Br Med Bull. 53:1997;478-790.
25. Johnson D.E. Noncaspase proteases in apoptosis. Leukemia. 14:2000;1695-1703.
26. Deveraux Q., Reed J.C. IAP family proteins - suppressors of apoptosis. Genes Dev. 13:1998;239-252.
27. Tamm I., Kornblau S.M., Segall H., et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 6:2000;1796-1803.
28. Takahashi R., Deveraux Q., Tamm I., et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem. 273:1998;7787-7790.
29. Antwerp D.J., Martin S.J., Kafri T., et al. Suppression of TNF-α-induced apoptosis by NF-κB. Science. 274:1996;787-789.
30. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:1997;917-921.
31. Tamm I., Wang Y., Sausville E., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:1998;5315-5320.
32. LaCasse E.C., Baird S., Korneluk R.G., MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 17:1998;3247-3259.
33. Li F., Ambrosini G., Chu E.Y., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:1998;580-584.
34. Suzuki A., Hayashida M., Ito T., et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk-4/p16INK4a and Cdk2/cyclin E complex activation. Oncogene. 19:2000;3225-3234.
35. Reed J.C. Survivin cell-separation anxiety. Nat Cell Biol. 1:1999;199-200.
36. Li F., Ackermann E.J., Bennett C.F., et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol. 1:1999;461-466.
37. Dierlamm J., Baens M., Wlodarska I., et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood. 93:1999;3601-3609.
38. Irmler M., Thome M., Hahne M., et al. Inhibition of death receptor signals by cellular FLIP. Nature. 388:1997;190-195.
39. Kataoka T., Schroter M., Hahne M., et al. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol. 161:1998;3936-3942.
40. Kataoka T., Budd R.C., Holler N., et al. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr Biol. 10:2000;640-648.
41. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science. 281:1998;1305-1308.
42. Hofmann K. The modular nature of apoptotic signaling proteins. Cell Mol Life Sci. 55:1999;1113-1128.
43. Tolomeo M., Dusonchet L., Meli M., et al. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ. 5:1998;735-742.
44. Friesen C., Herr I., Krammer P.H., Debatin K.-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug induced apoptosis in leukemia cells. Nat Med. 2:1996;574-577.
45. Wesselborg S., Engels I.H., Rossmann E., et al. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood. 93:1999;3053-3063.
46. Engels I.H., Stepczynska A., Stroh C., et al. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene. 19:2000;4563-4573.
47. Tartaglia L.A., Goeddel D.V. Two TNF receptors. Immunol Today. 13:1992;151-153.
48. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 271:1996;12687-12690.
49. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:1995;673-682.
50. Walczak H., Miller R.E., Ariail K., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 5:1999;157-163.
51. Ashkenazi A., Pai R.C., Fong S., et al. Safety and antitumor activityof recombinant soluble Apo2 ligand. J Clin Invest. 104:1999;155-162.
52. Jo M., Kim T.-H., Seoul D.-W., et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 6:2000;564-567.
53. Nagata S. Steering anti-cancer drugs away from the TRAIL. Nat Med. 6:2000;502-503.
54. Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res. 248:1999;30-43.
55. Jaattela M., Wissing D., Bauer P.A., Li G.C. Major heat shock protein hsp70 protects tumor cells from tumor necrosis factor cytotoxicity. EMBO J. 11:1992;3507-3512.
56. Langdon S.P., Rabiasz G.J., Hirst G.L., et al. Expression of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res. 1:1995;1603-1609.
57. Uozaki H., Horiuchi H., Ishida T., et al. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer. 79:1997;2336-2344.
58. Tsujimoto Y., Cossman J., Croce C. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 228:1985;1440-1443.
59. Campos L., Rouault J.P., Sabido O., et al. High expression of bcl-2-protein in acute myeloid leukemia is associated with poor response to chemotherapy. Blood. 81:1993;3091-3096.
60. Waters J.S., Webb A., Cunningham D., et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 18:2000;1812-1823.
61. Piche A., Grim J., Rancourt C., Gomez-Navarro J., Reed J.C., Curiel D.T. Modulation of bcl-2 protein levels by an intracellular anti-bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res. 58:1998;2134-2140.
62. Dorai T., Perlman H., Walsh K., et al. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int J Cancer. 82:1999;846-852.
63. Kunstle G., Leist M., Uhlig S., et al. ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-α Immunol Lett. 55:1997;5-10.
64. Griffith T.S., Lynch D.H. TRAIL: a molecule with multiplereceptors and control mechanisms. Curr Opin Immunol. 10:1998;559-563.
65. Vucic D., Kaiser W.J., Miller L.K. Inhibitor of apoptosis proteins physically interact with and block apoptosis induced by Drosophila proteins HID and GRIM. Mol Cell Biol. 18:1998;3300-3309.
66. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 102:2000;33-42.
67. Chai J., Du C., Wu J.-W., Kyin S., Wang X., Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature. 406:2000;855-862.
68. Wang C.Y., Cusack J.C., Liu R., Baldwin A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med. 5:1999;412-417.
69. Roth J.A., Nguyen D., Lawrence D.D., et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 2:1996;985-991.